CIBC Asset Management Inc acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,777 shares of the biopharmaceutical company’s stock, valued at approximately $221,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. First Manhattan Co. purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at $135,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at $148,000. Westpac Banking Corp purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at $202,000. Prudential Financial Inc. purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at $215,000. Finally, Capstone Asset Management Co. purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at $232,000. Institutional investors own 88.99% of the company’s stock.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at 81.42 on Monday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $31.38 and a 12 month high of $86.92. The firm’s market capitalization is $7.47 billion. The stock has a 50 day moving average of $80.83 and a 200 day moving average of $63.46.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.12. The business had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.05) EPS. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.21) earnings per share for the current fiscal year.

WARNING: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/21/cibc-asset-management-inc-invests-221000-in-alnylam-pharmaceuticals-inc-alny.html.

Several research analysts have recently weighed in on ALNY shares. Piper Jaffray Companies set a $116.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 24th. Ladenburg Thalmann Financial Services set a $80.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 17th. Vetr downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price for the company. in a report on Monday, May 15th. Chardan Capital reduced their target price on shares of Alnylam Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a report on Monday, May 15th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $102.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday, June 22nd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the stock. Alnylam Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $81.74.

In other news, major shareholder Sanofi acquired 297,501 shares of the business’s stock in a transaction dated Wednesday, May 31st. The stock was bought at an average cost of $71.87 per share, for a total transaction of $21,381,396.87. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Laurie Keating acquired 11,500 shares of the business’s stock in a transaction dated Tuesday, May 30th. The stock was purchased at an average price of $65.35 per share, with a total value of $751,525.00. Following the completion of the transaction, the senior vice president now directly owns 11,500 shares of the company’s stock, valued at approximately $751,525. The disclosure for this purchase can be found here. 4.30% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.